Celldex Therapeutics (CLDX) Accumulated Depreciation (2011 - 2025)

Celldex Therapeutics' Accumulated Depreciation history runs 15 years deep, the most recent figure standing at $23.9 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 1.88% year-over-year to $23.9 million; the TTM figure through Dec 2025 stood at $23.9 million (up 1.88% YoY), while the FY2025 annual figure was $23.9 million, up 1.88% from the prior year.
• Accumulated Depreciation was $23.9 million for Q4 2025 at Celldex Therapeutics, up from $23.5 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $23.9 million in Q4 2025 to a low of $21.1 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $22.5 million across 5 years, with a median of $22.4 million in 2023.
• The sharpest annual moves came in 2021 and 2024: Accumulated Depreciation declined 0.52% in 2021, then gained 4.82% in 2024.
• A 5-year view of Accumulated Depreciation shows it stood at $21.1 million in 2021, then grew by 2.37% to $21.6 million in 2022, then grew by 3.51% to $22.4 million in 2023, then climbed by 4.82% to $23.5 million in 2024, then increased by 1.88% to $23.9 million in 2025.
• The last three Accumulated Depreciation figures came in at $23.9 million (Q4 2025), $23.5 million (Q4 2024), and $22.4 million (Q4 2023), per Business Quant data.